GSK bid undervalues Human Genome, investor says






GSK bid undervalues Human Genome, investor says



A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company resultsLONDON (Reuters) - GlaxoSmithKline's $2.6 billion offer for Human Genome Sciences undervalues the biotech company, according to Taube Hodson Stonex, a leading investor in the U.S. group. "The price that's been offered, although it is a big premium to where the shares were trading, is not high enough," said Mark Evans, a fund manager at Taube, which is the sixth largest investor in Human Genome with a 5.6 percent stake. GSK, Britain's biggest drugmaker, says its $13 a share offer is "full and fair" and it is the only obvious owner for the U.S. ...









Popular posts from this blog

One dead, more than dozen hurt as storm rips through baseball party tent

Which Wedding Style Is The Best Fit For A Couple?

Greece opens detention camp for immigrants as election looms